Nelfinavir (DB00220): A Comprehensive Pharmacological and Clinical Monograph

Executive Summary

Nelfinavir, marketed under the brand name Viracept, is a first-generation, orally bioavailable, nonpeptidic human immunodeficiency virus (HIV) protease inhibitor (PI). It was a cornerstone of highly active antiretroviral therapy (HAART) following its landmark U.S. Food and Drug Administration (FDA) approval in 1997. As a potent competitive inhibitor of HIV-1 and HIV-2 protease, Nelfinavir's mechanism of action involves preventing the proteolytic cleavage of viral Gag-Pol polyproteins, a critical step in the viral life cycle. This inhibition results in the production of immature, non-infectious virions, thereby halting viral propagation. In combination with nucleoside reverse transcriptase inhibitors (NRTIs), Nelfinavir demonstrated the ability to produce substantial and sustained reductions in viral load and significant increases in CD4+ cell counts in both treatment-naïve and treatment-experienced patient populations.

The clinical utility of Nelfinavir is defined by a complex pharmacokinetic profile, characterized by a critical food effect for absorption, extensive hepatic metabolism by cytochrome P450 (CYP) isoenzymes CYP3A4 and CYP2C19, and a relatively short terminal half-life of 3.5 to 5 hours. Its safety profile is marked by a high incidence of gastrointestinal side effects, most notably diarrhea, and the potential for class-wide metabolic complications such as hyperglycemia and lipodystrophy. Furthermore, its potent inhibition of the CYP3A4 enzyme results in numerous clinically significant drug-drug interactions, a factor that complicates its use in patients on polypharmacy and has contributed to its decline in clinical practice.

While its primary resistance mutation, D30N, did not confer broad cross-resistance to other protease inhibitors—a notable advantage in the era of sequential therapy—Nelfinavir was ultimately superseded by newer antiretroviral agents. These next-generation drugs offered superior virologic efficacy, higher genetic barriers to resistance, more favorable tolerability profiles, and simpler, more convenient dosing regimens. Despite its diminished role in contemporary HIV therapy, Nelfinavir has become the subject of extensive repurposing research. Its pleiotropic, off-target effects—notably the inhibition of the Akt signaling pathway and the induction of endoplasmic reticulum stress—have established it as a broad-spectrum, preclinical anti-cancer agent. Concurrently, research into its activity against other viruses, such as SARS-CoV-2, has yielded promising in vitro data, although these findings have not yet translated to demonstrable clinical efficacy. Nelfinavir thus serves as a compelling case study in the rapid evolution of antiretroviral therapy and stands as a promising scaffold for future drug development, particularly in the field of oncology.

Drug Identification and Physicochemical Properties

A comprehensive understanding of Nelfinavir begins with its fundamental identity, established through standardized nomenclature, unique database identifiers, and a detailed characterization of its chemical and physical properties.

Nomenclature and Identifiers

Nelfinavir is recognized globally through a variety of names and registry numbers that ensure its unambiguous identification in clinical, research, and regulatory contexts.

• Generic Name: Nelfinavir [1]
• Brand Name: Viracept [4]
• Drug Type: Small Molecule [1]
• Database Identifiers:
• DrugBank ID: DB00220 [1]
• CAS Number: 159989-64-7 (for the free base); 159989-65-8 (for the mesylate salt) [2]
• PubChem CID: 64143 [2]
• Other Synonyms/Codes: NFV, AG1343, AG1341 [1]

Chemical Structure and Properties

The specific molecular architecture of Nelfinavir is the basis for its targeted interaction with HIV protease and its broader pharmacological profile.

• IUPAC Name: (3S,4aS,8aS)−N−tert−butyl−2−−4−(phenylsulfanyl)butyl]−decahydroisoquinoline−3−carboxamide [2]
• Molecular Formula: C32​H45​N3​O4​S [2]
• Molar Mass / Molecular Weight: The molecular weight of the free base is 567.79 g·mol⁻¹ (also reported as 567.78 g·mol⁻¹).[1] The clinically administered form, nelfinavir mesylate, has a molecular weight of 663.90 g·mol⁻¹.[10]
• Chemical Class: Nelfinavir is a complex synthetic organic molecule classified as an aryl sulfide. It incorporates several functional groups, including being a member of benzamides, a member of phenols, a secondary alcohol, and an organic heterobicyclic compound.[2] This intricate structure was rationally designed to fit within the active site of the HIV protease enzyme.

Physical Characteristics

The physical properties of Nelfinavir dictate its formulation, stability, and pharmacokinetic behavior, particularly its absorption from the gastrointestinal tract.

• Physical Description: Nelfinavir mesylate is a white to off-white crystalline or amorphous powder.[2]
• Melting Point: There is conflicting information regarding the melting point. One source reports it as 349.84 °C, while another indicates a range of 185-186 °C.[2] This discrepancy may be attributable to differences between the free base and the mesylate salt forms or variations in experimental measurement conditions.
• Solubility: The drug is slightly soluble in water, particularly at a pH below 4, and is freely soluble in organic solvents such as methanol, ethanol, and propylene glycol.[2]
• Lipophilicity (LogP): The partition coefficient (LogP) is reported to be 6.0, indicating that Nelfinavir is a highly lipophilic (fat-soluble) compound.[2] This high lipophilicity contributes to its extensive binding to plasma proteins and its distribution into various body tissues.

The decision to formulate and market Nelfinavir as a mesylate salt was a critical step in its development. Pharmaceutical compounds are frequently converted into salt forms to enhance their physicochemical properties, most notably solubility and dissolution rate, which are key determinants of oral bioavailability. The Nelfinavir free base is poorly soluble in water, presenting a significant challenge for creating an effective oral medication.[2] By forming the mesylate salt, the developers improved its aqueous solubility, especially in the acidic environment of the stomach (pH <4), thereby facilitating its absorption into the bloodstream.[10] This link between the drug's fundamental chemistry and its clinical application underscores the importance of pharmaceutical formulation in translating a potent molecule into a viable therapeutic agent.

Property	Description	Source(s)
Generic Name	Nelfinavir	1
Brand Name	Viracept	4
DrugBank ID	DB00220	1
CAS Number	159989-64-7 (free base); 159989-65-8 (mesylate salt)	2
Molecular Formula	C32​H45​N3​O4​S	2
Molar Mass	567.79 g/mol (free base); 663.90 g/mol (mesylate salt)	4
IUPAC Name	(3S,4aS,8aS)−N−tert−butyl−2−−4−(phenylsulfanyl)butyl]−decahydroisoquinoline−3−carboxamide	2
Physical Description	White to off-white crystalline or amorphous powder	2
Solubility	Slightly soluble in water at pH <4; freely soluble in methanol, ethanol	2
LogP	6.0	2

Regulatory History and Market Status

The regulatory and commercial trajectory of Nelfinavir reflects the dynamic and rapidly advancing landscape of HIV therapy, from its celebrated introduction to its eventual displacement by newer agents.

Development and Approval

Nelfinavir was the product of a collaboration between Agouron Pharmaceuticals and Eli Lilly and Company.[4] Following its patenting in 1992, it underwent clinical development that culminated in its approval by the U.S. FDA on March 14, 1997.[4] This approval, granted under the FDA's accelerated approval process, covered both the 250 mg tablet and a 50 mg/g oral powder for pediatric use, making Nelfinavir the twelfth antiretroviral agent to enter the U.S. market.[4] A higher-strength 625 mg tablet was subsequently approved on April 30, 2003.[17] The drug's launch was a major commercial success, achieving first-year sales exceeding $335 million and marking what was then the largest "biotech launch" in the history of the pharmaceutical industry.[4]

Manufacturer History and Marketing Rights

The corporate lineage of Nelfinavir's developer is complex. Agouron Pharmaceuticals was acquired by Warner-Lambert in 1999, which was subsequently acquired by Pfizer.[4] As a result, Pfizer now manages medical information for Viracept in the United States.[21] Global marketing rights are split, with Hoffman-La Roche responsible for the European market and ViiV Healthcare responsible for other regions.[4]

Global Regulatory Status

In the European Union, a marketing authorization for Viracept was granted to Roche Registration Limited by the European Commission on January 22, 1998.[22] This authorization was renewed for five-year periods in 2003 and 2008. However, the marketing authorization holder did not apply for a further renewal, and the authorization was allowed to expire on January 23, 2013, leading to the withdrawal of Viracept from the EU market.[22]

Significant Post-Marketing Events

A significant event in Nelfinavir's history occurred in June 2007, when European regulatory bodies, including the European Medicines Agency (EMA) and the UK's Medicines and Healthcare products Regulatory Agency (MHRA), issued a recall of Viracept.[4] The recall was initiated after some batches were found to be contaminated with ethyl mesilate, a genotoxic (potentially cancer-causing) chemical. This led to a temporary suspension of the marketing authorization and an FDA warning against its use in pregnant women.[22] While the issue was resolved and the suspension was lifted, this safety scare likely damaged prescriber and patient confidence in the drug.

Current Therapeutic Role

Although Nelfinavir remains FDA-approved for the treatment of HIV-1 infection in combination with other antiretroviral agents, its role in clinical practice has been significantly diminished.[24] Contemporary HIV treatment guidelines no longer recommend Nelfinavir for either initial or subsequent lines of therapy.[26] This is due to a combination of factors, including its inferior virologic efficacy compared to newer agents, a higher pill burden, significant toxicities, and a complex drug-drug interaction profile. It is now considered an alternative agent, primarily reserved as an option for patients who are unable to tolerate other, more modern protease inhibitors.[27]

The history of Nelfinavir serves as a microcosm of the evolution of HIV therapy itself. Its arrival in 1997 was a monumental step forward, helping to establish the paradigm of HAART and transforming HIV infection into a manageable chronic condition. At the time, its limitations—such as a high pill burden, a strict requirement to be taken with food, and a high incidence of diarrhea—were acceptable trade-offs for its life-saving efficacy.[4] However, the field of antiretroviral drug development progressed at an extraordinary pace. Subsequent generations of drugs offered profound improvements in convenience (once-daily dosing), tolerability, safety, and resistance profiles.[28] The 2007 contamination recall occurred at a time when these superior alternatives were becoming widely available, likely accelerating Nelfinavir's decline. Its eventual withdrawal from the European market in 2013 formally marked its transition from a frontline therapy to a legacy drug, a testament to how quickly the standard of care can be redefined by relentless innovation.[22]

Detailed Pharmacology and Mechanism of Action

Nelfinavir's therapeutic and investigational activities stem from its interactions with specific molecular targets, primarily the protease enzyme of HIV, but also extending to key pathways within human cells and other pathogens.

Primary Antiviral Mechanism (Anti-HIV)

Nelfinavir's primary therapeutic effect is the potent and selective inhibition of the aspartate protease enzymes encoded by HIV-1 and HIV-2.[1] This enzyme is absolutely essential for the virus to produce mature, infectious particles.

• Biochemical Potency and Action: During the late stages of the HIV replication cycle, the viral Gag-Pol gene is translated into large, non-functional polyprotein precursors.[1] HIV protease acts like a molecular scissor, cleaving these polyproteins at specific sites to release the individual functional proteins and enzymes (such as reverse transcriptase, integrase, and structural proteins) required to assemble a new virion.[1] Nelfinavir functions as a competitive inhibitor, binding tightly and reversibly to the active site of the protease with a high affinity, reflected by its low inhibition constant ( Ki​) of 2 nM.[4]
• Result of Inhibition: By occupying the active site, Nelfinavir physically blocks the protease from accessing and cleaving the Gag-Pol polyproteins.[1] This disruption prevents the final maturation step of the virus. Consequently, the viral particles that are assembled and released from the infected cell are structurally incomplete and non-infectious, unable to propagate the infection to new host cells.[1]

Structural Basis of Inhibition

The high potency and specificity of Nelfinavir are direct results of its rational, structure-based design, which optimized its fit within the three-dimensional structure of the HIV protease active site.[14]

• Molecular Design: Nelfinavir is a nonpeptidic molecule, meaning it is not a simple chain of amino acids. A key feature of its design is a central hydroxyl group which mimics the transition state of a natural peptide bond. This hydroxyl group forms critical hydrogen bonds with the catalytic aspartate residues (Asp-25 and Asp-25') in the floor of the active site, but unlike a peptide bond, it cannot be cleaved by the enzyme.[4]
• Active Site Interactions: X-ray crystallography studies of Nelfinavir bound to HIV protease have revealed the precise interactions that anchor it within the enzyme's binding pockets [14]:
• The lipophilic dodecahydroisoquinoline ring system fits snugly into the hydrophobic S1' subsite.
• The tert-butylcarboxamide moiety occupies the S2' subsite.
• The thiophenyl ether group resides in the S1 subsite.
• The 2-methyl-3-hydroxybenzamide portion occupies the S2 subsite. A crucial hydrogen bond forms between the inhibitor's meta-phenol group and the side chain of the Asp-30 residue of the protease. This specific interaction is believed to be a key factor in Nelfinavir's distinct resistance profile, particularly concerning the D30N mutation.

Off-Target Mechanisms and Repurposing Potential

Beyond its intended antiviral target, Nelfinavir interacts with various host cell proteins and pathways, leading to a range of effects that are being explored for therapeutic repurposing, most notably in oncology.

• Oncology: Since 2009, Nelfinavir has been investigated as a potential broad-spectrum anti-cancer agent based on observations of its activity in numerous cancer cell lines (including prostate, glioblastoma, and lung cancer) and in animal xenograft models.[4] Its anti-tumor activity appears to be driven by at least two primary mechanisms [4]:

1. Inhibition of the Akt/PKB Signaling Pathway: The PI3K/Akt pathway is a central regulator of cell growth, proliferation, and survival, and it is frequently hyperactivated in many forms of cancer. Nelfinavir has been shown to inhibit the phosphorylation and subsequent activation of Akt, thereby shutting down this pro-survival signaling cascade in tumor cells.[4]
2. Induction of Endoplasmic Reticulum (ER) Stress: Nelfinavir can induce a state of ER stress, which triggers the unfolded protein response (UPR). In cancer cells, sustained and overwhelming ER stress leads to programmed cell death (apoptosis).[4]

These primary actions result in a cascade of downstream anti-cancer effects, including reduced angiogenesis (inhibition of VEGF), decreased invasion and metastasis (inhibition of MMP-2 and MMP-9), cell cycle arrest, and enhanced apoptosis.29 Preclinical studies have shown its efficacy in models of small-cell lung cancer and have demonstrated synergistic effects when combined with other agents like chloroquine.40

• SARS-CoV-2: During the COVID-19 pandemic, Nelfinavir was identified in screening studies as having in vitro activity against SARS-CoV-2.[34] In silico modeling suggested that it might inhibit the SARS-CoV-2 main protease (3CLpro), analogous to its mechanism against HIV protease.[42] However, this promising preclinical activity did not translate into clinical benefit. A randomized controlled trial involving patients with mild COVID-19 found that Nelfinavir did not accelerate viral clearance or improve clinical symptoms and was associated with a higher incidence of adverse events, primarily diarrhea.[45]
• Anti-Virulence Activity: Nelfinavir has also demonstrated the ability to inhibit the production of virulence factors, such as the cytolysin streptolysin S, in the pathogenic bacterium Streptococcus pyogenes. This action occurs without direct antibiotic activity, suggesting a novel anti-virulence mechanism that could potentially disarm bacteria without promoting antibiotic resistance.[4]

The pharmacology of Nelfinavir provides a compelling illustration of how a drug's off-target effects can be both a clinical liability and a therapeutic opportunity. The same molecular mechanism—inhibition of the Akt signaling pathway—is responsible for both undesirable side effects in HIV treatment and promising anti-cancer activity. In the context of HIV therapy, inhibition of Akt in normal tissues like adipocytes and hepatocytes is implicated in the development of insulin resistance and hyperglycemia, well-known metabolic side effects of the protease inhibitor class.[29] In cancer cells, however, where the Akt pathway is often pathologically overactive and drives malignant growth, this same inhibitory action becomes a highly desirable therapeutic effect.[4] This duality demonstrates that the biological consequence of a drug-target interaction is entirely context-dependent. It reveals how a deep understanding of the molecular basis for a drug's adverse event profile can be a powerful tool for drug repurposing, directly bridging the gap between Nelfinavir's safety limitations in virology and its potential efficacy in oncology.

Comprehensive Pharmacokinetic Profile

The pharmacokinetic profile of Nelfinavir—its absorption, distribution, metabolism, and excretion (ADME)—is complex and characterized by significant variability, which has profound implications for its clinical use and has been a key factor in its replacement by newer agents.

Absorption

• Bioavailability and Food Effect: The oral bioavailability of Nelfinavir is variable, with estimates ranging from 20% to 80%.[48] This variability is largely dictated by the presence of food. Administration with a meal is critical, as it substantially increases drug exposure (both peak plasma concentration, Cmax​, and area under the concentration-time curve, AUC) by two- to five-fold and reduces pharmacokinetic variability compared to the fasted state.[4] This potent food effect is a major clinical consideration and necessitates strict patient counseling to ensure therapeutic drug levels are achieved.
• Formulation Differences: The two available tablet strengths are not bioequivalent. Under fasted conditions, the 625 mg tablet results in a 34% higher AUC and a 24% higher Cmax​ compared to the 250 mg tablet formulation.[10]

Distribution

• Plasma Protein Binding: Nelfinavir is highly bound to plasma proteins, with over 98% of the drug in circulation attached to proteins like albumin.[4] This extensive binding limits the concentration of free, pharmacologically active drug but also creates a circulating reservoir.
• Volume of Distribution: The apparent volume of distribution (Vd​) is estimated to be between 2 and 7 L/kg, indicating that the drug distributes from the plasma into tissues.[50] Population pharmacokinetic modeling has estimated the apparent volume of distribution (V/F) to be approximately 309 to 351 L.[51]

Metabolism

• Site and Enzymes: Nelfinavir undergoes extensive metabolism, primarily in the liver.[4] This process is mediated by the cytochrome P450 system, with isoenzymes CYP3A4 and, to a lesser extent, CYP2C19 being the main enzymes responsible for its breakdown.[4] This reliance on CYP3A4 is the primary reason for Nelfinavir's extensive and clinically significant drug-drug interactions.
• Metabolites: Following administration, unchanged Nelfinavir constitutes 82-86% of the total drug-related material in plasma.[10] The biotransformation process yields one major oxidative metabolite, known as M8 (nelfinavir hydroxyl-t-butylamide), which retains antiviral activity comparable to that of the parent compound.[1]

Excretion

• Route of Elimination: The primary route of elimination for Nelfinavir and its metabolites is through the biliary system into the feces. Approximately 87% of an administered dose is recovered in the feces, with about 78% of this being metabolites and 22% being unchanged drug.[4]
• Renal Elimination: Renal excretion plays a minimal role, with only 1-2% of the dose recovered in the urine.[4] Consequently, no dose adjustment is required for patients with renal impairment.
• Half-Life: The terminal plasma half-life of Nelfinavir is consistently reported to be in the range of 3.5 to 5 hours.[1]

Pharmacokinetics in Special Populations

• Pregnancy: The profound physiological changes that occur during pregnancy have a significant impact on Nelfinavir's pharmacokinetics. Studies have demonstrated that in the third trimester, drug clearance is increased and the AUC is substantially decreased compared to non-pregnant women. This leads to lower trough concentrations, raising concerns about the potential for subtherapeutic drug exposure, which could risk both maternal virologic control and perinatal HIV transmission.[52]
• Pediatric Patients: The pharmacokinetics of Nelfinavir in children are characterized by extremely high inter-patient variability. This is thought to be due to factors such as inconsistent food intake relative to dose administration and potentially higher drug clearance rates compared to adults. This high variability makes it difficult to establish a reliably effective dose and poses a significant challenge to achieving consistent therapeutic concentrations in this population.[50]
• Hepatic Impairment: While no dose adjustment is needed for patients with mild hepatic impairment (Child-Pugh Class A), moderate hepatic impairment (Child-Pugh Class B) results in a 62% increase in Nelfinavir AUC. Therefore, its use is not recommended in patients with moderate or severe hepatic impairment.[50]

The demanding and often unpredictable pharmacokinetic profile of Nelfinavir was a major factor in its eventual decline in clinical use. Effective antiretroviral therapy relies on maintaining drug concentrations consistently above the virus's inhibitory threshold to ensure durable suppression and prevent the emergence of resistance. Nelfinavir's significant food effect introduces a major source of variability; administration without an adequate meal can lead to subtherapeutic drug levels and an increased risk of treatment failure.[32] The high inter-patient variability, especially pronounced in children, complicates dosing and increases the risk of both under-dosing (risking resistance) and over-dosing (risking toxicity).[53] Furthermore, the decreased drug exposure observed during pregnancy presents a critical challenge in a population where maintaining complete viral suppression is paramount.[52] Newer antiretroviral agents were specifically developed to overcome these types of pharmacokinetic flaws, offering more robust, predictable absorption with fewer food restrictions. The "forgiveness" of a drug's pharmacokinetic profile—its ability to maintain therapeutic levels despite minor deviations in administration—is a critical determinant of its long-term clinical utility. Nelfinavir's unforgiving profile made it a less reliable and more challenging drug to manage in real-world clinical settings, contributing directly to its replacement by more pharmacokinetically robust alternatives.

Parameter	Value / Description	Source(s)
Bioavailability	Variable (20-80%); oral clearance suggests medium to high hepatic bioavailability.	1
Effect of Food	Absorption and exposure (AUC, Cmax​) increase 2- to 5-fold with food; variability is decreased. Must be taken with a meal.	4
Protein Binding	>98%	4
Volume of Distribution	2–7 L/kg	50
Metabolism	Extensive hepatic metabolism via CYP3A4 and CYP2C19.	4
Major Metabolite	M8 (Nelfinavir hydroxyl-t-butylamide), which is antivirally active.	1
Elimination Half-life	3.5–5 hours	1
Route of Excretion	Primarily feces (87%); minimal renal excretion (1–2%).	4

Clinical Efficacy and Therapeutic Use

Nelfinavir's clinical application is primarily for the treatment of HIV-1 infection, as established through a series of clinical trials in various patient populations.

Approved Indications

• Nelfinavir, in combination with other antiretroviral agents, is indicated for the treatment of HIV-1 infection.[24]
• It is approved for use in adults, adolescents, and pediatric patients aged 2 years and older in the United States.[26] The European approval was for use in patients aged 3 years and older.[22]
• It has also been listed as a component of an alternative regimen for nonoccupational postexposure prophylaxis (nPEP) of HIV infection.[6]

Summary of Clinical Trial Efficacy

The efficacy of Nelfinavir has been evaluated in numerous clinical trials, which formed the basis of its approval and defined its role in HAART.

• Treatment-Naïve Adults: In pivotal trials, Nelfinavir demonstrated potent antiviral activity when combined with NRTIs. In Study 511, a regimen of Nelfinavir (750 mg TID) with zidovudine and lamivudine resulted in 86% of patients achieving an HIV RNA level below 400 copies/mL at 48 weeks, with a robust mean increase in CD4+ cell count of approximately 208 cells/mm³.[26] Study 542 established that a twice-daily regimen of 1250 mg was comparable in efficacy to the 750 mg three-times-daily regimen, offering a potential simplification of dosing.[26]
• Treatment-Experienced Adults: In patients with prior antiretroviral experience, Nelfinavir also showed efficacy. However, in a head-to-head comparison study (ACTG 364), a Nelfinavir-based regimen was found to be virologically inferior to a regimen containing the NNRTI efavirenz at 48 weeks.[50]
• Pediatric Patients: Efficacy in children aged 2 years and older was established in Study 556, where 26% of children on a Nelfinavir-containing regimen achieved HIV RNA <400 copies/mL at 48 weeks, compared to only 2% in the placebo group.[50] However, clinical data indicated that response rates were poorer in children under 2 years of age, and high pharmacokinetic variability remains a significant challenge in the pediatric population.[50]
• Use in Pregnancy: Nelfinavir has been evaluated for use during pregnancy, including in a Phase 3 trial (NCT00017719).[57] It was previously recommended in some treatment guidelines for this population due to its established safety and efficacy profile at the time.[27] However, concerns regarding altered pharmacokinetics during the second and third trimesters and a less favorable adverse event profile have led to current recommendations favoring alternative agents during pregnancy.[50]

Dosing and Administration

Correct administration of Nelfinavir is crucial for achieving therapeutic efficacy, with specific guidelines for different patient populations and formulations.

• Critical Administration Guideline: To ensure adequate absorption and bioavailability, all doses of Viracept must be taken with a meal.[24]

Patient Population	Dosing Regimen	Formulation(s)	Key Administration Notes
Adults & Adolescents (≥13 years)	1250 mg twice daily (BID) OR 750 mg three times daily (TID)	250 mg and 625 mg Tablets	Must be taken with a meal. Tablets may be dissolved in a small amount of water if unable to swallow.
Pediatric Patients (2 to <13 years)	BID Regimen: 45–55 mg/kg OR TID Regimen: 25–35 mg/kg	250 mg Tablets and 50 mg/g Oral Powder	Must be taken with a meal. Dosage is based on body weight; refer to prescribing information for specific dosing charts. Oral powder should not be mixed with acidic foods/juices.

• Administration for Patients Unable to Swallow Tablets: The tablets can be placed in a small amount of water, allowed to dissolve into a cloudy liquid, mixed well, and consumed immediately. The glass should be rinsed with water and the rinse also swallowed to ensure the full dose is taken.[24]
• Oral Powder Administration: The oral powder should be mixed with a small amount of a non-acidic liquid or soft food, such as water, milk, formula, or dietary supplements. It should not be mixed with acidic items like orange juice or apple sauce, as this can result in a bitter taste. The mixture should be consumed immediately or, if necessary, can be stored under refrigeration for a maximum of 6 hours.[24]

Safety, Tolerability, and Risk Management

The safety profile of Nelfinavir is characterized by frequent gastrointestinal adverse effects, the potential for class-wide metabolic complications, and a high propensity for drug-drug interactions, all of which require careful clinical management.

Adverse Drug Reactions

• Most Common (≥2% incidence): The most prominent adverse effect associated with Nelfinavir is diarrhea, which can be moderate to severe and is reported in up to 20% of adults and as high as 47% of children.[4] Other common gastrointestinal complaints include nausea and flatulence. Rash is also a frequently reported side effect.[4]
• Less Common and Serious Adverse Events: Less frequent but more serious adverse events have been reported. These include hepatitis and mouth ulcers.[4] Postmarketing experience has identified rare but severe reactions such as jaundice, QTc interval prolongation, torsades de pointes, metabolic acidosis, and hypersensitivity reactions (including bronchospasm and edema).[24]

Metabolic Complications (Protease Inhibitor Class Effects)

Like other drugs in its class, Nelfinavir is associated with a syndrome of metabolic complications:

• Diabetes Mellitus and Hyperglycemia: New-onset diabetes, exacerbation of existing diabetes, and hyperglycemia have been reported in patients receiving protease inhibitors. Patients should be monitored for symptoms of high blood sugar, such as excessive thirst (polydipsia), frequent urination (polyuria), and weakness.[25]
• Fat Redistribution (Lipodystrophy): Changes in body fat distribution have been observed with long-term antiretroviral therapy. This can manifest as central obesity, accumulation of fat on the upper back and neck (dorsocervical fat pad or "buffalo hump"), breast enlargement, and loss of fat from the limbs and face (peripheral wasting).[25]
• Hyperlipidemia: Elevations in serum cholesterol and triglycerides can occur during treatment.[30]

Specific Warnings and Precautions

• Hepatic Impairment: Nelfinavir should not be used in patients with moderate or severe hepatic impairment (Child-Pugh Class B or C) due to increased drug exposure.[54]
• Hemophilia: There have been reports of increased bleeding, including spontaneous skin hematomas and hemarthrosis, in patients with hemophilia type A and B treated with protease inhibitors.[25]
• Phenylketonuria (PKU): The oral powder formulation contains the artificial sweetener aspartame, which is metabolized to phenylalanine. It should therefore be used with caution in individuals with PKU.[25]
• Immune Reconstitution Syndrome: In patients with advanced HIV infection and severe immunodeficiency, the initiation of ART can lead to an inflammatory response to previously undiagnosed, indolent opportunistic infections (e.g., Mycobacterium avium complex, cytomegalovirus). This phenomenon requires careful monitoring and management.[25]

Contraindications and Drug-Drug Interactions

Nelfinavir's clinical use is heavily constrained by its extensive drug-drug interaction profile, which stems from its potent inhibition of the CYP3A4 enzyme.

The central role of the CYP3A4 enzyme in Nelfinavir's clinical profile cannot be overstated. The drug's relationship with this enzyme is bidirectional and defines its most significant clinical challenges. As a substrate of CYP3A4, Nelfinavir's own metabolism is susceptible to being altered by other drugs. Co-administration with a potent CYP3A4 inducer, such as the antibiotic rifampin, can dramatically accelerate Nelfinavir's clearance, leading to subtherapeutic plasma concentrations and a high risk of virologic failure and drug resistance.[50] Conversely, as a potent

inhibitor of CYP3A4, Nelfinavir blocks the metabolism of a vast array of other medications that depend on this pathway for their clearance.[2] This is often the more dangerous interaction, as it can cause the concentrations of co-administered drugs (e.g., certain statins, antiarrhythmics, or sedatives) to rise to toxic or even life-threatening levels. This dual role creates a complex web of potential interactions that demands extreme vigilance from clinicians and severely limits therapeutic options for patients with common comorbidities, representing a major liability that contributed to its replacement by agents with cleaner interaction profiles.

Contraindicated Medications:

• Due to risk of serious toxicity from increased co-administered drug levels: Co-administration is contraindicated with drugs like alfuzosin, amiodarone, cisapride, ergot derivatives (dihydroergotamine, ergotamine), lovastatin, simvastatin, pimozide, and orally administered midazolam or triazolam.[50]
• Due to risk of Nelfinavir treatment failure: Co-administration is contraindicated with potent CYP3A4 inducers like rifampin and the herbal product St. John's wort, which can cause a profound reduction in Nelfinavir plasma concentrations.[50]

Interacting Drug/Class	Mechanism of Interaction	Effect on Drug Concentrations	Clinical Recommendation/Management
Antimycobacterials
Rifampin	Potent CYP3A4 induction	↓↓↓ Nelfinavir	Contraindicated. Risk of loss of virologic response and resistance.
Rifabutin	CYP3A4 induction/inhibition	↓ Nelfinavir, ↑↑ Rifabutin	Reduce rifabutin dose by 50%. Use Nelfinavir 1250 mg BID regimen.
Anticonvulsants
Carbamazepine, Phenobarbital	CYP3A4 induction	↓ Nelfinavir	Avoid concomitant use if possible. May lead to loss of therapeutic effect.
Phenytoin	CYP3A4 induction/inhibition	↓ Nelfinavir, ↓ Phenytoin	Monitor phenytoin concentrations closely; dose adjustments may be needed.
HMG-CoA Reductase Inhibitors (Statins)
Simvastatin, Lovastatin	CYP3A4 inhibition by Nelfinavir	↑↑↑ Statin	Contraindicated. Increased risk of myopathy and rhabdomyolysis.
Atorvastatin	CYP3A4 inhibition by Nelfinavir	↑ Atorvastatin	Use with caution. Start with the lowest possible atorvastatin dose and titrate carefully. Do not exceed 40 mg/day.
Proton Pump Inhibitors
Omeprazole	Unknown; may reduce absorption	↓ Nelfinavir	Avoid concomitant use. May lead to loss of virologic response.
Hormonal Contraceptives
Ethinyl estradiol, Norethindrone	CYP3A4 induction by Nelfinavir	↓ Contraceptive levels	Nelfinavir can decrease the effectiveness of oral contraceptives. Use of alternative or additional (non-hormonal) contraceptive measures is recommended.
Herbal Products
St. John's Wort	Potent CYP3A4 induction	↓↓↓ Nelfinavir	Contraindicated. Risk of loss of virologic response and resistance.
Other Antiretrovirals
Didanosine (ddI)	Absorption interaction	No significant effect on Nelfinavir	Administer didanosine 1 hour before or more than 2 hours after Nelfinavir. Didanosine must be taken on an empty stomach, while Nelfinavir must be taken with food.

Viral Resistance

The development of drug resistance is a major challenge in HIV therapy. Nelfinavir's resistance profile is characterized by specific genetic mutations in the viral protease gene that reduce the drug's binding affinity and efficacy.

Mechanisms of Resistance

• HIV-1 isolates with reduced susceptibility to Nelfinavir can be selected both in vitro and, more importantly, can emerge in patients experiencing virologic failure during therapy.[32]
• Primary Resistance Mutation: The signature mutation most commonly associated with Nelfinavir resistance, particularly in patients infected with HIV-1 subtype B, is a substitution at codon 30 of the protease gene, from aspartic acid to asparagine (D30N).[27] In some clinical studies, this mutation was detected in over half of the patients who failed a Nelfinavir-containing regimen.[50]
• Other Associated Mutations: While D30N is the hallmark mutation, other substitutions can also contribute to Nelfinavir resistance, either alone or in combination. These include mutations at positions 35, 36, 46, 71, 77, 88, and notably, the L90M mutation.[10]

Cross-Resistance Profile

The pattern of cross-resistance—where mutations conferring resistance to one drug also confer resistance to other drugs in the same class—is a critical factor in planning subsequent treatment regimens.

• Advantage of the D30N Mutation: A key clinical feature of the D30N mutation is its limited cross-resistance profile. Viruses harboring the D30N mutation typically remain susceptible to other protease inhibitors, including amprenavir, indinavir, lopinavir, and saquinavir.[4] This was a significant advantage in the early era of HAART, as virologic failure on a Nelfinavir-based regimen did not necessarily preclude the successful use of other PIs in a salvage regimen.
• The L90M Mutation: In contrast, the L90M mutation, which can also be selected by Nelfinavir, is a major PI resistance mutation that is associated with broad cross-resistance across the entire class of first-generation protease inhibitors.[10]
• Comparison to Second-Generation PIs: Newer, second-generation PIs like darunavir were specifically designed to overcome resistance. They exhibit potent activity against HIV-1 isolates that are resistant to multiple first-generation PIs and possess a much higher "genetic barrier" to resistance. This means that the virus must accumulate a greater number of specific mutations to overcome the drug's inhibitory effect, making the development of resistance a slower and less frequent event.[28]

The evolution in understanding viral resistance is clearly illustrated by comparing Nelfinavir to a modern PI like darunavir. In the early days of combination therapy, when treatment failure was more common, the primary goal was to manage a sequence of different regimens over a patient's lifetime. In this paradigm, a drug like Nelfinavir, which tended to fail "cleanly" via the D30N mutation without compromising future options within its class, was highly valuable.[4] It was often considered a good "first PI" for this reason. However, the therapeutic goal has since shifted from managing sequential failures to achieving durable, lifelong viral suppression with an initial, highly effective regimen. Second-generation PIs like darunavir were engineered for this modern goal. Their high potency and unique binding interactions mean they have a high genetic barrier to resistance, making virologic failure and the emergence of resistance much less probable from the outset.[28] This strategic shift in drug design—from creating drugs that fail in a manageable way to creating drugs that are extremely difficult to fail—represents a fundamental advance in antiretroviral therapy. The concept of a high genetic barrier has thus become a more critical clinical attribute than a unique but low-barrier resistance pathway.

Conclusion and Future Perspectives

Nelfinavir holds a significant place in the history of HIV medicine as a pivotal, yet ultimately transitional, therapeutic agent. As one of the first potent, orally available protease inhibitors, its introduction as part of HAART in 1997 was instrumental in transforming the clinical course of HIV/AIDS from a rapidly fatal disease to a manageable chronic condition. It established the profound efficacy of targeting the HIV protease enzyme and provided years of life-saving therapy for countless individuals. However, its long-term utility was ultimately constrained by a series of inherent limitations: a challenging pharmacokinetic profile heavily dependent on food for absorption, a high daily pill burden, significant gastrointestinal toxicity dominated by diarrhea, and a complex and high-risk drug-drug interaction profile stemming from its potent inhibition of CYP3A4. As the field of antiretroviral therapy rapidly advanced, Nelfinavir was superseded by newer agents offering greater potency, higher barriers to resistance, improved tolerability, and the convenience of once-daily dosing.

The most compelling chapter in Nelfinavir's ongoing story lies in the field of drug repurposing. The discovery of its potent, off-target anti-cancer activity has opened a new avenue of investigation, transforming the molecule from a legacy antiviral into a promising lead compound for oncology. Its well-characterized safety and pharmacokinetic profile, established over more than two decades of clinical use, provides a valuable foundation that can potentially accelerate its development for new indications.[35] The pleiotropic mechanisms by which it attacks cancer cells—simultaneously inhibiting the critical Akt survival pathway and inducing lethal endoplasmic reticulum stress—make it a particularly attractive candidate for use in combination with other established chemotherapeutics or radiation therapy.[4]

While Nelfinavir itself is highly unlikely to see a resurgence in HIV clinics, its molecular scaffold and its complex pharmacology continue to provide valuable lessons. The failure of its promising in vitro activity against SARS-CoV-2 to translate into clinical benefit serves as a crucial reminder of the immense challenges in drug repurposing, highlighting the importance of matching in vivo drug exposure and pharmacodynamics to the specific requirements of a new disease target.[45] Ultimately, the future of Nelfinavir lies not in its original indication, but as a powerful research tool and a proof-of-concept for the development of novel, multi-targeted agents designed to combat complex diseases like cancer. Its journey from a frontline antiviral to a potential anti-cancer therapeutic exemplifies the dynamic and often unpredictable lifecycle of a pharmaceutical compound.

Works cited

1. Nelfinavir: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed August 4, 2025, https://go.drugbank.com/drugs/DB00220
2. Nelfinavir | C32H45N3O4S | CID 64143 - PubChem, accessed August 4, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Nelfinavir
3. nelfinavir | Ligand page | IUPHAR/BPS Guide to PHARMACOLOGY, accessed August 4, 2025, https://www.guidetopharmacology.org/GRAC/LigandDisplayForward?ligandId=11090
4. Nelfinavir - Wikipedia, accessed August 4, 2025, https://en.wikipedia.org/wiki/Nelfinavir
5. www.cancer.gov, accessed August 4, 2025, https://www.cancer.gov/publications/dictionaries/cancer-drug/def/nelfinavir-mesylate
6. Nelfinavir - brand name list from Drugs.com, accessed August 4, 2025, https://www.drugs.com/ingredient/nelfinavir.html
7. Nelfinavir - LiverTox - NCBI Bookshelf, accessed August 4, 2025, https://www.ncbi.nlm.nih.gov/books/NBK548311/
8. Nelfinavir (AG1341) | HIV Protease Inhibitor | AmBeed.com, accessed August 4, 2025, https://www.ambeed.com/products/nelfinavir.html
9. CAS 159989-64-7 Nelfinavir - BOC Sciences, accessed August 4, 2025, https://www.bocsci.com/product/nelfinavir-cas-159989-64-7-455040.html
10. VIRACEPT - accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2005/021503s006lbl.pdf
11. Nelfinavir | CAS 159989-64-7 | SCBT - Santa Cruz Biotechnology, accessed August 4, 2025, https://www.scbt.com/p/nelfinavir-159989-64-7
12. Nelfinavir (AG1341) | HIV Protease Inhibitor - MedchemExpress.com, accessed August 4, 2025, https://www.medchemexpress.com/nelfinavir.html
13. Nelfinavir - CAS Common Chemistry, accessed August 4, 2025, https://commonchemistry.cas.org/detail?cas_rn=159989-64-7
14. Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease | Journal of Medicinal Chemistry - ACS Publications, accessed August 4, 2025, https://pubs.acs.org/doi/10.1021/jm9704098
15. en.wikipedia.org, accessed August 4, 2025, https://en.wikipedia.org/wiki/Nelfinavir#:~:text=HIV%2D2%20proteases.-,History,and%20elsewhere%20by%20ViiV%20Healthcare.
16. Viracept (Nelfinavir Mesylate, AG1343): A Potent, Orally Bioavailable Inhibitor of HIV-1 Protease | Journal of Medicinal Chemistry - ACS Publications, accessed August 4, 2025, https://pubs.acs.org/doi/abs/10.1021/jm9704098
17. Generic Viracept Availability - Drugs.com, accessed August 4, 2025, https://www.drugs.com/availability/generic-viracept.html
18. CENTER FOR DRUG EVALUATION AND RESEARCH - accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/97/020778ap.pdf
19. FDA Approves Viracept, New Protease Inhibitor - CancerNetwork, accessed August 4, 2025, https://www.cancernetwork.com/view/fda-approves-viracept-new-protease-inhibitor
20. www.accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/nda/2003/021503s000_ViraceptTOC.cfm#:~:text=Approval%20Date%3A%204%2F30%2F2003
21. VIRACEPT (nelfinavir mesylate) | Pfizer Medical - US, accessed August 4, 2025, https://www.pfizermedical.com/viracept
22. Viracept | European Medicines Agency (EMA), accessed August 4, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/viracept
23. Notice to Readers: Updated Information Regarding Antiretroviral Agents Used as HIV Postexposure Prophylaxis for Occupational HIV Exposures - CDC, accessed August 4, 2025, https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5649a4.htm
24. highlights of prescribing information - Pfizer, accessed August 4, 2025, https://labeling.pfizer.com/ShowLabeling.aspx?id=528
25. Nelfinavir: MedlinePlus Drug Information, accessed August 4, 2025, https://medlineplus.gov/druginfo/meds/a697034.html
26. Nelfinavir: uses, dosing, warnings, adverse events, interactions - TheBodyPro, accessed August 4, 2025, https://www.thebodypro.com/drugs/monograph/236-397034/nelfinavir-oral
27. Nelfinavir: a review of its use in the management of HIV infection - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/16225378/
28. Resilience to Resistance of HIV-1 Protease Inhibitors: Profile of ..., accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2699666/
29. Nelfinavir and other protease inhibitors in cancer: mechanisms involved in anticancer activity. - F1000Research, accessed August 4, 2025, https://f1000research.com/articles/4-9
30. Nelfinavir | Drug Lookup | Pediatric Care Online - AAP Publications, accessed August 4, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/5525/Nelfinavir
31. What is the mechanism of Nelfinavir Mesylate? - Patsnap Synapse, accessed August 4, 2025, https://synapse.patsnap.com/article/what-is-the-mechanism-of-nelfinavir-mesylate
32. VIRACEPT - accessdata.fda.gov, accessed August 4, 2025, https://www.accessdata.fda.gov/drugsatfda_docs/label/2011/020778s035,020779s056,021503s017lbl.pdf
33. Nelfinavir mesylate | DrugBank Online, accessed August 4, 2025, https://go.drugbank.com/salts/DBSALT000885
34. HIV protease inhibitors Nelfinavir and Lopinavir/Ritonavir markedly improve lung pathology in SARS-CoV-2-infected Syrian hamsters despite lack of an antiviral effect, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC8978445/
35. The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir - MDPI, accessed August 4, 2025, https://www.mdpi.com/2072-6694/12/11/3437
36. Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo | Clinical Cancer Research - AACR Journals, accessed August 4, 2025, https://aacrjournals.org/clincancerres/article-abstract/13/17/5183/164083
37. Drug Discovery Using Chemical Systems Biology: Weak Inhibition of ..., accessed August 4, 2025, https://journals.plos.org/ploscompbiol/article?id=10.1371/journal.pcbi.1002037
38. Nelfinavir, A lead HIV protease inhibitor, is a broad-spectrum, anticancer agent that induces endoplasmic reticulum stress, autophagy, and apoptosis in vitro and in vivo. | Cellular & Molecular Medicine, accessed August 4, 2025, https://cmm.arizona.edu/publications/nelfinavir-lead-hiv-protease-inhibitor-broad-spectrum-anticancer-agent-induces
39. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/18006837/
40. Nelfinavir Inhibits the Growth of Small-cell Lung Cancer Cells and Patient-derived Xenograft Tumors | Anticancer Research, accessed August 4, 2025, https://ar.iiarjournals.org/content/41/1/91
41. Combining Nelfinavir With Chloroquine Inhibits In Vivo Growth of Human Lung Cancer Xenograft Tumors, accessed August 4, 2025, https://iv.iiarjournals.org/content/35/1/141
42. Research suggests Nelfinavir and Cepharanthine as potential anti ..., accessed August 4, 2025, https://www.news-medical.net/news/20200419/Research-suggests-Nelfinavir-and-Cepharanthine-as-potential-anti-SARS-CoV-2-agents.aspx
43. Nelfinavir: An Old Ally in the COVID-19 Fight? - MDPI, accessed August 4, 2025, https://www.mdpi.com/2076-2607/10/12/2471
44. Multidrug treatment with nelfinavir and cepharanthine against COVID-19 | bioRxiv, accessed August 4, 2025, https://www.biorxiv.org/content/10.1101/2020.04.14.039925v1
45. A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19 | Microbiology Spectrum, accessed August 4, 2025, https://journals.asm.org/doi/10.1128/spectrum.04311-22
46. A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19 - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/37140398/
47. A Multicenter Randomized Controlled Trial To Evaluate the Efficacy and Safety of Nelfinavir in Patients with Mild COVID-19 | Microbiology Spectrum - ASM Journals, accessed August 4, 2025, https://journals.asm.org/doi/abs/10.1128/spectrum.04311-22?af=R
48. Nelfinavir mesylate: a protease inhibitor - PubMed, accessed August 4, 2025, https://pubmed.ncbi.nlm.nih.gov/10200859/
49. NELFINAVIR: REVISION DE SU FARMACOCINÉTICA E INTERACCIONES MEDICAMENTOSAS | Farmacia Hospitalaria - Elsevier, accessed August 4, 2025, https://www.elsevier.es/es-revista-farmacia-hospitalaria-121-articulo-nelfinavir-revision-de-su-farmacocinetica-13005174
50. Viracept Dosage Guide - Drugs.com, accessed August 4, 2025, https://www.drugs.com/dosage/viracept.html
51. Population pharmacokinetic analysis for nelfinavir and its metabolite M8 in virologically controlled HIV-infected patients on HAART - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1884828/
52. Pharmacokinetics of nelfinavir in HIV-1-infected pregnant and nonpregnant women - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC1885131/
53. Pharmacokinetics and Pharmacodynamics of Nelfinavir Administered Twice or Thrice Daily to Human Immunodeficiency Virus Type 1-Infected Children | Clinical Infectious Diseases | Oxford Academic, accessed August 4, 2025, https://academic.oup.com/cid/article/36/11/1476/305885
54. Nelfinavir (oral route) - Side effects & dosage - Mayo Clinic, accessed August 4, 2025, https://www.mayoclinic.org/drugs-supplements/nelfinavir-oral-route/description/drg-20065021
55. Viracept, INN-nelfinavir mesilate, accessed August 4, 2025, https://ec.europa.eu/health/documents/community-register/2010/2010012073128/anx_73128_en.pdf
56. Nelfinavir Dosage Guide + Max Dose, Adjustments - Drugs.com, accessed August 4, 2025, https://www.drugs.com/dosage/nelfinavir.html
57. Nelfinavir Completed Phase 3 Trials for Pregnancy / Human Immunodeficiency Virus (HIV) Infections Treatment | DrugBank Online, accessed August 4, 2025, https://go.drugbank.com/drugs/DB00220/clinical_trials?conditions=DBCOND0035016%2CDBCOND0018394&phase=3&purpose=treatment&status=completed
58. VIRACEPT (nelfinavir mesylate) Dosage and Administration | Pfizer ..., accessed August 4, 2025, https://www.pfizermedical.com/viracept/dosage-admin
59. Nelfinavir: general information, study results (CD4 and viral load), dosing schedule, eating instructions, drug interactions, co - NATAP, accessed August 4, 2025, https://natap.org/1998/drug/nelfpkg.PDF
60. Nelfinavir Mesylate | C33H49N3O7S2 | CID 64142 - PubChem, accessed August 4, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/64142
61. Combating HIV resistance – focus on darunavir - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC2621389/
62. Full article: Pooled resistance analyses of darunavir once-daily regimens and formulations across 10 clinical studies of treatment-naïve and treatment-experienced patients with human immunodeficiency virus-1 infection - Taylor & Francis Online, accessed August 4, 2025, https://www.tandfonline.com/doi/full/10.1080/25787489.2020.1794439
63. The Anti-Cancer Properties of the HIV Protease Inhibitor Nelfinavir - PMC, accessed August 4, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC7699465/